Recent Updates
Recently added Catalysts

DEFINITY

Phase 3

Cardiac Disease | Small molecule | Other |Lantheus Holdings, Inc.|Last Updated: Jan 28, 2021

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLEDBiomarker
Total Trials2
Total Enrollment313
FDA Designations
No designations recorded
Clinical Trials (2)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT03719612DEF-315 Better Accuracy in Ejection Fraction (EF) Assessment With DEFINITYPHASE3 COMPLETED 160Dec 28, 2018Jan 9, 2020Jan 28, 202115 United States
NCT03571672DEF-314 Better Accuracy in Ejection Fraction (EF) Assessment With DEFINITYPHASE3 COMPLETED 153Oct 24, 2018Aug 30, 2019Dec 17, 20209 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Absolute Value of LVEF Percentage Differences From CMR by Blinded Reader
Up to 30 days between day of echocardiograms and CMR imaging

Demonstrate improvement in accuracy in left ventricular ejection fraction (LVEF) assessment using DEFINITY® contrast-enhanced over unenhanced echocardiography by comparing LVEF percentage differences from CMR measured by 3 independent blinded image readers.

Secondary Endpoints
Secondary Objective 1: Absolute Value of LVEF Percentage Differences From CMR by Blinded Reader for Sub-optimal Echocardiograms
Up to 30 days between day of echocardiogram and CMR imaging
Secondary Objective 2: Absolute Value LVEF Percentage Differences From CMR Between Blinded Readers
Up to 30 days between day of echocardiograms and CMR imaging
Secondary Objective 3: Absolute Value End-diastolic and Systolic Volume Differences From CMR Between Blinded Readers
Up to 30 days between day of echocardiogram and CMR imaging
Unlock Study Endpoints
Study Design & Arms
AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeDIAGNOSTIC
Treatment Arms
ArmTypeDescription
DEFINITY®EXPERIMENTALEach patient will undergo an unenhanced ultrasound examination and a DEFINITY® contrast-enhanced ultrasound
DEFINITYEXPERIMENTALEach patient will undergo an unenhanced ultrasound examination and a DEFINITY contrast-enhanced ultrasound
Interventions
NameTypeDescription
DEFINITY®DRUGAll subjects will receive a single dose of DEFINITY®
DEFINITYDRUGAll subjects will receive a single dose of DEFINITY®
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites15

Inclusion Criteria: 1. Men and women ≥ 18 years of age in sinus rhythm 2. Able to communicate effectively with trial personnel 3. LVEF measurements obtained via 2D Echo with or without contrast obtained within 6 months prior to enrollment (Day 0) 4. Has provided signed informed consent after receiv...

Countries:United States
Unlock Eligibility Criteria